RxDoctor Payments Data

Bettina Smith

Family · Brooksville, FLNPI 1245980655

Payments from drug & device makers

$4,955in general payments, 2019–2025

Across 170 payments — averaging $29.15 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Neurocrine Biosciences, Inc.$686
  • Otsuka America Pharmaceutical, Inc.$613
  • Teva Pharmaceuticals USA, Inc.$573
  • E.r. Squibb & Sons, L.L.C.$526
  • Alkermes, Inc.$505
  • AbbVie$446
  • plus $2K from 9 others

What the payments were for

  • Food & beverage$4,84898%
  • Education$1072%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,955 in reported general payments places this provider in the 90th percentile of 14,618 family providers in Florida.

See all family providers in Florida

Medicare billing

Part B allowed, 2024
$44,539
Medicare patients
161
Services billed
516

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Buspirone Hcl108$1,666
Olanzapine29$1,482
Duloxetine Hcl63$1,395
Desvenlafaxine Succinate ErDesvenlafaxine Succinate13$1,350
Quetiapine Fumarate34$1,061
Fluoxetine Hcl65$1,011
Trazodone Hcl46$589
Clonazepam43$562
Lorazepam75$449
Bupropion XlBupropion Hcl20$432
Mirtazapine26$411
Alprazolam61$352
Hydroxyzine Pamoate26$279
Divalproex Sodium16$224
Aripiprazole12$211

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Almatica Pharma LLCSertraline Hcl$162$8320 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 14,618 family providers in Florida.

Other family in Brooksville

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →